Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
For TNG462, we dosed the first patient in the phase 1/2 trial in July 2023.
- For TNG462, we dosed the first patient in the phase 1/2 trial in July 2023.
- Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, November 1-5, 2023, San Diego, CA
In November 2023, Tango scientists presented preclinical data highlighting the potential of TNG260 in STK11-mutant cancers. - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11-15, 2023, Boston, MA
In October 2023, Tango scientists presented five posters highlighting preclinical data from the precision oncology pipeline and synthetic lethality discovery platform. - The year-to-date increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.